New Orleans, LA - Research led by Nicolas Bazan, MD, PhD, Boyd Professor and Director of the Neuroscience Center of Excellence at LSU Health Sciences Center New Orleans, has found that a synthetic molecule protected the brain in a model of experimental stroke. Dr. Bazan was issued a patent on the molecule called LAU-0901, a low molecular weight drug that crosses the blood-brain barrier. The findings are published in the March 2012 issue of Translational Stroke Research.
During an ischemic stroke, the most common kind, the body releases signals that cause neuroinflammation which leads to a buildup of chemicals that harm the brain. Platelet-activating factor (PAF) accumulates, and inhibition of this process plays a critical role in neuronal survival.
"LAU-0901 is able to reduce this incorrect signaling and inhibit the PAF receptor, which reduces multiple neuroinflammatory signals and greatly lessens the severity of damage in experimental stroke," notes Dr. Bazan.
The research team used magnetic resonance imaging in conjunction with behavior and immunohistopathology to further study this novel therapeutic approach. The researchers report that LAU-0901, given two hours after the onset of experimental stroke, lessened the severity of brain damage, significantly reduced lesions in the brain, and improved coordination and movement. LAU-0901 produced no discernible side effects. These findings suggest LAU-0901 is a promising neuroprotectant that provides the basis for future therapeutics in patients suffering ischemic stroke.
Stroke is a leading cause of death and disability worldwide. Conventional therapies for ischemic stroke include thrombolytic therapy, prevention of inappropriate coagulation and thrombosis, and surgery to repair vascular abnormalities.Only one FDA-approved therapy exists for treatment of acute ischemic stroke, the thrombolytic tissue plasminogen activator (tPA), but only 5% of all ischemic stroke patients are eligible for treatment with tPA.
The research team also included Professor Ludmila Belayev and MD/PhD student Tiffany Niemoller Eady at LSU Health Sciences Center New Orleans, as well as Dr. Julio Alvarez Builla and other scientists from the University of Alcala, Spain, and Dr. Andre Obenaus at the University of Loma Linda.
LSU Health Sciences Center New Orleans educates Louisiana's health care professionals. The state's academic health leader, LSUHSC consists of a School of Medicine, the state's only School of Dentistry, Louisiana's only public School of Public Health, the only School of Nursing within an academic health center in Louisiana, and Schools of Allied Health Professions, and Graduate Studies. LSUHSC faculty take care of patients in public and private hospitals and clinics throughout the region. In the vanguard of biosciences research in a number of areas in a worldwide arena, the LSUHSC research enterprise generates jobs and enormous economic impact. LSUHSC faculty have made lifesaving discoveries and continue to work to prevent, advance treatment, or cure disease. To learn more, visit http://www.lsuhsc.edu and http://www.twitter.com/LSUHSCHealth.
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.